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Abstract
Background: Submicroscopic imbalances in the subtelomeric regions of the chromosomes are
considered to play an important role in the aetiology of mental retardation (MR). The aim of the
study was to evaluate a quantitative PCR (qPCR) protocol established by Boehm et al. (2004) in the
clinical routine of subtelomeric testing.
Results: 296 patients with MR and a normal karyotype (500–550 bands) were screened for
subtelomeric imbalances by using qPCR combined with SYBR green detection. In total, 17 patients
(5.8%) with 20 subtelomeric imbalances were identified. Six of the aberrations (2%) were classified
as causative for the symptoms, because they occurred either de novo in the patients (5 cases) or
the aberration were be detected in the patient and an equally affected parent (1 case). The extent
of the deletions ranged from 1.8 to approximately 10 Mb, duplications were 1.8 to approximately
5 Mb in size. In 6 patients, the copy number variations (CNVs) were rated as benign
polymorphisms, and the clinical relevance of these CNVs remains unclear in 5 patients (1.7%).
Therefore, the overall frequency of clinically relevant imbalances ranges between 2% and 3.7% in
our cohort.
Conclusion: This study illustrates that the qPCR/SYBR green technique represents a rapid and
versatile method for the detection of subtelomeric imbalances and the option to map the
breakpoint. Thus, this technique is highly suitable for genotype/phenotype studies in patients with
MR/developmental delay and/or congenital defects.
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Background
Mental retardation (MR) is a major health problem affect-
ing 3% of the population[1]. The aetiologies of MR are
manifold and include exogenic factors such as prenatal
infections, prenatal exposure to teratogenic substances,
perinatal asphyxia or genetic factors. However, in up to
60% of the patients the aetiology remains unclear. Chro-
mosomal abnormalities are responsible in 5 to 10% of
cases [2]. A substantial proportion of imbalances are
microscopically cryptic in routine karyotyping, but can be
recognized when analyzing the chromosome ends with
more subtle techniques.
Subtelomeric rearrangements are detected in patients with
unspecific MR in 3–6% as reviewed by Ledbetter and Mar-
tin [3]. In newborns with congenital defects, the detection
rate for subtelomeric aberrations is even higher with
9.86% [4]. Therefore, subtelomeric analysis became an
important tool in the diagnosis of idiopathic MR, devel-
opmental delay (DD) and congenital defects.
Various protocols have been developed to assess subtelo-
meric aberrations. Most laboratories use fluorescent in-
situ hybridisation (FISH) by commercially available BAC
probes. Microsatellite polymorphisms were also utilized
to detect deletions and duplications [5]. This technique is
practically limited by the requirement of parental samples
in each case. More recently, multiplex ligation-dependent
probe amplification (MLPA) [6] via commercially availa-
ble kits became widely used. The various diagnostic
attempts were reviewed by Rooms et al. [7]. We estab-
lished a quantitative PCR (qPCR) approach for subtelom-
eric screening [8]. A probe set of primers for all
subtelomeric regions was validated on 20 controls and 20
patients.
Screening of all subtelomeres by PCR based techniques
helps to reduce costs when compared to the FISH method,
which is the most widely used technique. The first objec-
tive of our study was to assess the feasibility of the qPCR
approach for subtelomeric screening in routine diagnos-
tics. The second aim was to evaluate whether pre-selection
of patients based on family history, pre- and postnatal
growth retardation and facial and non-facial dysmor-
phism as suggested by de Vries et al. [9] can help to
improve the predictive value of subtelomeric screening.
Here, we report on a cohort of individuals with normal
karyotyping who have MR, DD and/or congenital defects
of unknown cause. This is the first clinical application of
a qPCR/SYBR green approach for the detection of subtelo-
meric imbalances.
Results
Among the 296 patients analyzed, 17 (5.7%) were found
to have subtelomeric imbalances. In total, 10 deletions
and 10 duplications were identified. Details of the
patients with abnormal assay results are given in Table 1.
In 5 out of 17 patients, the subtelomeric rearrangement
occurred de novo. These aberrations were classified as
causative for the phenotype. A deletion or duplication of
a subtelomeric region was assessed as a clinically irrele-
vant polymorphism (copy number polymorphism, CNP)
if a parent with a normal phenotype had the same aberra-
tion. Six out of 20 subtelomeric rearrangements were clas-
sified as CNPs, because they were detected in the patients'
phenotypically normal mother or father. One child bears
a de novo deletion on chromosome 1q as well as an inher-
ited duplication on chromosome 2p. The mother of
patient 6 carries the same deletion on chromosome 6q as
her mentally retarded son and is known to display a sim-
ilar phenotype. Therefore, it can be assumed that this
abnormality is also relevant for the phenotype of the
patient. In the remaining 4 cases it was not possible to dis-
tinguish a causative mutation versus a CNP, because
parental DNA samples were not available for analysis.
The distribution of the de Vries score [9] in our cohort is
shown in Table 2. The median de Vries score of all 296
patients included was 2.55 (range 0–9). Two out of six
patients with a causative aberration had a de Vries score of
3 or higher.
Clinical and molecular findings in patients with confirmed 
causative subtelomeric aberrations (further details in table 
1)
Patient 1, with a terminal deletion of 13q (9.2 to 11.9 Mb)
and a terminal duplication of 9p (7.8 to 8.3 Mb) is a boy
with psychomotor DD. His parents were healthy, and
pregnancy was uneventful. He was born small-for-date,
body weight, height and occipito-frontal circumference
(OFC) stayed below the 3rd percentile. On physical exam-
ination at the age of 5 months (height 66 cm, body weight
6340 g, OFC 40.5 cm) he presented with hypertelorism,
ptosis, enophthalmus of the left eye, epicanthic folds (see
figures 1, a–c), micropenis with cryptorchidism, clubfeet
and an overriding 2nd and 4th toe on both feet. The
patient was hypotonic but moved all extremities sponta-
neously, grabbed objects and passed them to the other
hand. Hearing was impaired; a cranial magnetic reso-
nance imaging (MRI) showed slightly enlarged ventricles
and subarachnoid spaces. Ultrasound examination of the
heart revealed a mild kinking of the aorta. An abdominal
ultrasound was normal. MLPA confirmed the qPCR
results in the patient; FISH analysis of the patient was not
performed. Both parents showed normal results in qPCR
and FISH analyses, respectively. The duplicated region on
chromosome 9p contains at least 68 genes; the deleted
region on chromosome 13q encompasses at least 59
genes. To our knowledge, so far no other patient with a
similar genotype has been described.Molecular Cytogenetics 2009, 2:10 http://www.molecularcytogenetics.org/content/2/1/10
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Table 1: Characteristics of patients with subtelomeric aberrations identified by quantitative PCR
Case No. Age Sex Aberration
deletion (del)
duplication (dup)
Inheritance Approximate size 
(Mb, Kb)
Clinical Features 
(in addition to MR/
DD)
de Vries Score
15  m o md e l  1 3 q
dup 9p
de novo
de novo
9.2–11.9 Mb
7.8–8.3 Mb
epicanthic folds; 
hypertelorism; strabism; 
microcephaly; small 
stature, kinking of the 
aorta; clubfeet; 
micropenis; cryptorchism; 
hypotonia; impaired 
hearing
8
2 1 y 5 mo f del 11q
dup 6p
de novo
de novo
8.5–9.5 Mb
1.8–2.3 Mb
hypertelorism; round 
face, low set ears; 
posteriorly rotated ears; 
microcephaly; small 
stature; clinodactyly of 
both 4th fingers; hearing 
loss; hypotonia; wide 
spaced nipples; complex 
heart defect
6
3 10 days m del 4p de novo 1.9–7.7 Mb growth retardation, 
microcephaly, prominent 
glabella, high forehead, 
prominent nasal bridge, 
hypertelorism, 
micrognathia, bilateral 
single transverse palmar 
creases, clubfeet
5
4 1 y 11 mo f del 1q
dup 2p
de novo
paternal
5.6–7.1 Mb
n.d. (CNP)
microcephaly, small 
stature, prominent 
forehead, synostosis of 
the frontal suture, large 
earlobes, high palate, cleft 
uvula, hypoplastic finger 
and toe nails
4
5 2 y 7 mo f dup 19q de novo 4.8–5.0 Mb prominent forehead, deep 
hair line, broad nasal 
bridge, epicanthus, 
downward slanting 
palpebral fissures, low set 
and posteriorly rotated 
ears, short neck, midface 
hypoplasia; dystrophy; 
pectus carinatum (11)
2
6 5 y 4 mo m del 6q maternal* 4.2–5.3 Mb high forehead, long 
philtrum, overfolded helix 
of both ears, hypotonia
1
7 14 y 3 mo f del 1q n. e.
normal sister showed 
no aberration
> 1.42 Mb broad, flat nasal bridge; 
anteverted nares; 
epicanthus; refractive 
anomaly; flat philtrum; 
dental crowding; atrial 
septal defect; 
microcephaly; epilepsy; 
hearing loss; hypotonia; 
talipes valgus and falt feet; 
tapering fingers; cortical 
atrophy; hip dislocation
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Patient 2, with a terminal 11q deletion (8.5 to 9.5 Mb)
and a terminal 6p duplication (1.8 to 2.3 Mb), is a girl
with psychomotor DD and a complex heart defect (dou-
ble outlet right ventricle, pulmonary stenosis, atrial septal
defect). She was born small-for-date to healthy parents.
On physical examination at the age of 17 months, (height
69 cm, body weight 7800 g OFC 44.5 cm; all below the
3rd percentile) the following facial dysmorphic features
were noted: round face, low set and posteriorly rotated
ears, depressed nasal bridge, anteverted nares, hyperte-
lorism and an open mouth (see figure 1, d–f)). On both
hands, a clinodactyly of the 4th finger was noted, and the
patient had wide spaced nipples. The phenotype is remi-
niscent of Down syndrome. The heart defect was surgi-
cally corrected, and a profound bilateral deafness was
treated with hearing aids. The patient crawled at 12
8 5 mo f dup 1p n. e. > 1.75 Mb retrogenia; high palate; 
pterygium colli; broad 
nasal bridge; anteverted 
nares; hypertelorism; 
strabismus; low set ears; 
overfolded helices; 
microcephaly; atrial septal 
defect; urachus cyst; wide 
distance of mamillas; 
ventrally positioned anus; 
hypotonia
5
9 13 y 5 mo m del 21q n. e. 2.4–4.9 Mb low set ears; broad nasal 
bridge; anteverted nares; 
refractive anomaly; 
retarded bone age; 
autism; tapering fingers; 
long toes;
4
10 10 y 9 mo f del 20q n. e. > 274 Kb no additional features 0
11 7 y 1 mo m dup 10q n. e. 110–180 Kb hypertelorism; balcony 
forehead; hyperopia; 
hypotonia; hypothyreosis; 
hearing loss; clinodactyly; 
retardation of 
myelination;
5
12 7 y 2 mo f dup 10q paternal n.d. (CNP) severe MR; hearing loss; 
ataxia; seizures; autism;
3
13 9 y 8 mo m dup 7p n. e. > 792 Kb epicanthus 0
14 10 mo m dup 7p paternal n.d. (CNP) epilepsy; short tapering 
fingers; clinodactyly; club 
feet; sandals' gap
6
15 9 y 2 mo f dup 7p maternal n.d. (CNP) retardation of speech 0
16 4 y 4 mo m del 5p paternal n.d. (CNP) microcephaly; small 
stature; hypotonia; 
clinodactyly; plump, big 
fingers; sandals' gap; pes 
adductus; pharyngeal cyst; 
arachnoid cyst; latent 
hypothyreosis; growth 
hormone deficiency
5
17 3 y 11 mo m del 8p maternal n.d. (CNP) retardation of speech; 
hemihypertrophy
0
n. e. = not examined; n. d. = not determined; m = male; f = female; MR = mental retardation; DD = developmental delay, y = years, mo = months, 
*mother also mentally retarded, de novo in the mother, CNP = copy number polymorphism
Table 1: Characteristics of patients with subtelomeric aberrations identified by quantitative PCR (Continued)Molecular Cytogenetics 2009, 2:10 http://www.molecularcytogenetics.org/content/2/1/10
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months, walked unassisted with 16 months and uttered a
few words at 17 months. Testing for a 22q11.2 microdele-
tion (DiGeorge syndrome) and a mutation screening in
the PTPN11 gene (Noonan syndrome) revealed no muta-
tion. MLPA confirmed the qPCR results in the patient.
Subtelomeric FISH analyses confirmed a deletion of
11qter and revealed an additional 6pter signal on the long
arm of the same chromosome 11. These aberrations
occurred most likely de novo in the patient, because both
parents had normal results in qPCR and FISH assays. The
duplicated region on chromosome 6p contains at least 16
genes; and haploinsufficiency on chromosome 11q affects
at least 275 genes. In many aspects, the phenotype of the
patient resembles the 11q terminal deletion disorder
(Jacobsen syndrome, OMIM 147791). Surprisingly,
thrombocytopenia was not found in our patient, a symp-
tom present in almost all Jacobsen syndrome patients
[10].
Patient 3, with a terminal 4p deletion (1.99 to 7.7 Mb) is
a boy with profound psychomotor DD. He was born after
a 35 weeks of pregnancy with a birth weight of 1490 g, a
body height of 43.5 cm and an OFC of 30 cm (all <3rd
percentile). Physical examination at age 10 days revealed
marked growth retardation, microcephaly, a prominent
glabella, high forehead, prominent nasal bridge, hyperte-
lorism, micrognathia, bilateral single transverse palmar
creases and clubfeet. The deletion includes at least the
Wolf-Hirschhorn syndrome (WHS) critical region. The
deletion was confirmed via FISH analysis in the patient;
both parents had normal karyotypes and FISH results.
Therefore, a de novo WHS was diagnosed in the patient.
Unfortunately, the exact size of the deletion could not be
mapped, because further DNA from the patient was una-
vailable.
Patient 4, with a terminal 1q deletion (5.64 to 7.14 Mb),
is a girl with psychomotor DD. The patient was born to
unrelated healthy parents after an uneventful pregnancy
at 39 weeks (birth weight 2900 g (25th percentile), OFC
32 cm (3rd percentile)). Developmental milestones were
delayed and at the age of 18 months the patient could sit
unassisted. At physical examination the patient was 24
months old. She presented as a friendly, mentally retarded
child with a body weight of 13 kg (90th percentile), a
height of 84 cm (25th percentile) and an OFC of 41.3 cm
(2.5 cm below the 3rd percentile). Dysmorphic features
Table 2: Summary of patients' checklist scores (de Vries et al. [9])
Checklist score total number of cases cases with causal aberration cases with unclear impact of aberration
06 6 1 1
1–2 94 1 0
3–4 80 1 1
5–9 56 3 3
(Polymorphisms are excluded)
Photographs of three patients with subtelomeric aberrations Figure 1
Photographs of three patients with subtelomeric 
aberrations. Patient 1 at the age of 5 months (a-c). Patient 2 
at the age of 2 4/12 years (d) and at the age of 5 1/12 years 
(e, f). Patient 4 at the age of 1 11/12 years (g-i).
a bc
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comprised microcephaly, prominent forehead, synostosis
of the frontal suture, large earlobes, high palate, cleft
uvula and a thin upper lip (see figures 1, g–i). Finger and
toe nails were hypoplastic. At 23 months of age a cerebral
MRI showed globally delayed myelinisation and dysgene-
sis of the corpus callosum. Testing for FragileX syndrome
revealed no abnormality. The terminal 1q deletion was
confirmed using both FISH and MLPA analyses. Both par-
ents had normal karyotypes and normal FISH results,
respectively. A small duplication of chromosome 2pter
was additionally detected in the patient via qPCR. This
aberration was also present in the healthy father and
therefore considered to be a polymorphism. However, the
terminal 1q deletion arose de novo in the patient and
includes at least 124 genes. Altogether, the patient dis-
plays many typical signs, e.g. facial dysmorphisms and
brain anomalies that were previously described for other
patients with a similar sized deletion of chromosome
1qter [11].
Patient 5, with a terminal duplication of chromosome
19q (4.82 to 5.0 Mb), was previously described in detail
[12]. The girl is the second child of healthy, non-consan-
guineous parents. After a normal pregnancy she was born
in the 39th week of gestation with normal body weight,
height and OFC. Her developmental milestones were
delayed (crawling at 16 months, walking at 2 4/12 years,
five words at 2 7/12 years). At the time of investigation she
was 2 7/12 years old and presented with a prominent fore-
head, deep hair line, broad nasal bridge, epicanthus,
downward slanting palpebral fissures, low set and poste-
riorly rotated ears, short neck, midface hypoplasia, poor
weight gain (body length and OFC on 25th percentile,
body weight on 3rd percentile) and hypotonia. Cranial
MRI showed a thin corpus callosum. Testing for metabolic
disorders, EEG, echocardiography, abdominal ultra-
sound, and an X-ray of the left hand was normal. The
duplicated region in 19qter contains at least 182 genes. In
the child the 19qter duplication could be confirmed with
a subtelomeric FISH probe for 19q. An additional signal
for 19q subtelomere could be identified on the long arm
of chromosome 6. Both parents had normal karyotypes
and normal FISH results, respectively.
Patient 6, with a deletion of 6qter (4.2 to 5.3 Mb), was
born to a mother with MR. His father was treated for an
unspecified psychiatric illness, but was not reported to be
mentally retarded or suffering from other symptoms sim-
ilar to those of his son. The boy was born after a normal
pregnancy (birth weight of 3100 g (25th percentile),
height of 48 cm (25th percentile), OFC of 35 cm (50th
percentile). Developmental milestones were delayed. At
the age of 18 months the patient could sit unassisted, he
started to walk at 2 years. Speech development was also
delayed. During early childhood, the patient had devel-
oped absence-like generalized seizures which persisted in
low frequency under medication. At the time of investiga-
tion, the patient was 6 6/12 years old; body weight was
21.5 kg (50th percentile), body height 116 cm (25th per-
centile) and OFC 50 cm (3rd – 10th percentile). His men-
tal status was assessed as MR. He presented with a high
forehead, long philtrum and an overfolded helix of both
ears. The boy was hypotonic and slightly dysmetric in the
finger-nose test. An abdominal ultrasound was normal.
The deleted region in 6qter contains at least 46 genes. The
6qter deletion was detected by qPCR and confirmed by
subtelomeric FISH. The mother of the patient also suf-
fered from a MR, but she showed no further symptoms
such as epilepsy. She also had a normal karyotype at 600
bands resolution. However, using qPCR analysis and FISH
technique a subtelomeric deletion on chromosome 6q
was detected in the mother as well. Both maternal grand-
parents are healthy and of normal intelligence. The grand-
parents each had a normal karyotype and no subtelomeric
aberrations were detected by qPCR. Thus, the 6qter dele-
tion was maternally inherited in the index patient and
occurred de novo in his affected mother.
Discussion
In 5 out of 17 patients in this study the aberration
occurred de novo; two of them had complex rearrange-
ments with both a duplication and a deletion (patients 1
and 2). As shown by testing the parental samples, none of
the abnormalities detected in this study was derived from
a parental balanced translocation. Lacking of familial
cases is not in line with the observations in large studies
[13,14] who assessed that 60% and 50% of pathogenic
imbalances, respectively, originated from a parent with a
balanced translocation. However, paternity was not
checked in our study.
In 5 patients the aberrations detected were inherited from
an unaffected parent. These deletions and duplications
were rated as familial polymorphisms. Recently, several
studies demonstrated that large parts of the human
genome and especially the subtelomeric regions are varia-
ble in copy number in healthy subject [15,16]. Copy
number variations (CNVs) are much more common than
previously thought [17]. Our findings also indicate that
dosage polymorphisms are frequent and not conclusively
determined. Adeyinka et al. [18] reported that one third of
the subtelomeric deletions in mentally retarded patients
are found in an unaffected parent. But at least in theory,
the familial occurrence can not completely exclude a con-
tribution to the phenotype in an affected individual. For
example, three of our patients (patients 6, 16 and 17) had
familial deletions, which might affect the phenotype by
unmasking a heterozygous mutation. Assuming that the
maternally derived deletion in patient 6 is indeed patho-
genic, the boy expresses a much more severe phenotypeMolecular Cytogenetics 2009, 2:10 http://www.molecularcytogenetics.org/content/2/1/10
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than his mother. Variable expression, a phenomenon well
known especially in diseases with a dominant mode of
inheritance, would be an explanation for the phenotypi-
cal differences.
One (patient 12) of two patients with a small dup10q
inherited the abnormality from his unaffected father.
Recently, duplication of the 10q subtelomere region was
described as a common familial variant [14,15], and the
size of the 10q imbalance in normal individuals was up to
>7.8 Mb [15]. Thus, we propose a benign CNV in one of
our other patients (patient 11) with a dup10q despite
lacking parental samples.
Three patients carried a duplication of the 7p subte-
lomere; two of the duplications were inherited from the
unaffected mother. To date, the 7p telomere end was not
reported to show a copy number variation in large clinical
studies (reviewed by Balikova et al. [15]) and the accord-
ing region is not mentioned as being variable in copy
numbers in the Database of Genomic Variants http://
projects.tcag.ca/variation/?source=hg18. However, we
assume that we detected a new CNV. In general, also
familial duplications should be addressed carefully. Rod-
riguez et al. [19] pointed out that a familial duplication
could very well be the cause for affected offspring with
apparently the same aberration as the healthy parent. A
subtle new rearrangement of the parental duplication dur-
ing meiosis could result in an altered expression of the
relocated genes in the affected child due to a positional
effect.
It was not possible to assess the clinical significance in the
remaining four cases (patients 8 to 11).
The frequency of MR caused by subtelomeric imbalances
in various studies differs widely from 2 to 29% (reviewed
by Ravnan et al. [14]). Reasons for this great difference
include resolution of prior karyotyping and inclusion cri-
teria. Not all authors excluded the possibility of polymor-
phisms consistently. Considering large studies, the
frequency of truly cryptic subtelomeric abnormalities is
estimated to be 2.6% [20] and 2.5% [14]. An overview of
previous studies is given in table 3[13,14,20-27]. From
the present data we assess that in about half of the 17
patients with an abnormal result the imbalances turned
out to be causative for the clinical findings in the patient.
The remaining aberrations were rated as benign variants.
Table 3: Surveys estimating the prevalence of significant subtelomere imbalances in individuals with mental retardation and normal 
cytogenetic results
Reference Assay used in study Number
of cases
Inclusion/selection criteria No of patients with clinically 
relevant aberrations
Vorsanova et al., 1998 (27) FISH 209 children with MR 8 (3.8%)
Knight et al., 1999 (13) FISH 466 children and young adults with MR 22 (4.7%)
Riegel et al., 2001 (24) FISH 254 MR plus dysmorphic signs 13 (5.1%)
Baker at al., 2002 (21) FISH 250 MR/DD with and without 
dysmorphisms
9 (3.6%)
Van Karnebeek et al., 2002 (26) FISH 266 MR 29 (10.9%)
Jalal et al., 2003 (22) FISH 372 MR with and without dysmorphisms 24 (6.5%)
Yu et al., 2005 (20) FISH 543 MR with and without dysmorphisms, 
newborns with malformations/
dysmorphisms
7 (1.3%)
Ravnan et al., 2006 (14) FISH 11,688 MR/DD with a wide range of 
indications
303 (2.6%)
Koolen et al., 2004 (23) MLPA 210 MR 7 (4.3%)
Rooms et al., 2006 (25) MLPA 275 MR 8 (2.9%)
Present study qPCR 296 MR with and without dysmorphisms 11 (3.7%)
FISH, fluorescence in situ hybridisation; MLPA, multiplex ligation dependent probe amplification; qPCR, quantitative PCRMolecular Cytogenetics 2009, 2:10 http://www.molecularcytogenetics.org/content/2/1/10
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Therefore, we estimate that the frequency of true causative
mutations is approximately 3% in our sample population.
In the literature, the most commonly reported clinically
significant imbalances were deletions of chromosomes
1p, 22q, 9q, 8p, 2q, and 20p [14]. In our study, after an
exclusion of all polymorphisms, imbalances include dif-
ferent aberrations: deletions of 4p, 6q, 11q, 13q and
duplications of 2p, 6p, 19p and 19q.
In 2001, a five-item clinical checklist was suggested [9] as
a means of improving the rate of detection of subtelom-
eric defects among patients with MR. In two thirds of our
patients with subtelomeric imbalances, the score sug-
gested by de Vries was ≥ 3 (see table 2). However, even
after a clinical reassessment, two patients (patient 5 and
6) had idiopathic MR with only minor features regarding
the de Vries score (de Vries score of 2 and 1, respectively).
The results of the present study support the assumption
that preselecting patients for subtelomeric testing by fam-
ily history, physical features and growth abnormalities
can improve the sensitivity of the screening. Nonetheless,
subtelomeric aberrations as a cause for idiopathic MR
without associated dysmorphic features are well described
[21] and the de Vries checklist score depends on the qual-
ity of the clinical observation. Because subtelomeric test-
ing is a relatively uncomplicated diagnostic procedure, it
should therefore be considered in patients with unex-
plained MR.
FISH using commercially available probes was established
ten years ago and it is the most widely used technology in
subtelomeric screening [28]. However, FISH requires
chromosome preparation, is labour intensive and expen-
sive. Polymorphic marker analysis for the detection of
subtelomeric imbalances was reported [5]. This technique
is automatable, however, the availability of samples of
both parents in every case and heterozygosity of a substan-
tial number of loci are indispensable requirements for
analysis. Compared to microsatellite analysis, quantita-
tive techniques such as qPCR as well as MLPA do not
require parental samples. Quantitative PCR is useful in
reducing the workload significantly. It can easily be estab-
lished in laboratories equipped for molecular genetic
diagnostics (ABI System is used for the detection) and is
suitable for automated screening. Recently, Udaka et al.
[29] developed an assay for the assessment of subtelom-
eric copy numbers using the primer set by Boehm et al. [8]
and detection by multiplex PCR/liquid chromatography.
This attempt is of advantage for those laboratories having
WAVE technology available, but usually laboratories will
not have the ability to perform liquid chromatography. So
far no clinical study of a population of mentally retarded
individuals has been reported with this method. With
commercially available FISH and MLPA kits alone, in
most cases it is not possible to address the extension of a
detected aberration. In order to study the extension of
subtelomeric imbalances, Ballif et al. [30] developed an
array CGH approach with a targeted BAC microarray,
using probes situated every 0.5 Mb and covering on aver-
age 5.7 Mb from the telomere. This strategy allows break-
point mapping within a range of 1 Mb but requires the
establishment of the BAC array technology.
The qPCR approach presented in our study allows the pre-
cise determination of the extension of the imbalance. The
breakpoint can be narrowed down to less than 1 kb, if
primers are selected individually. This could be demon-
strated recently in two patients [12,31]. Detailed analysis
of the size and breakpoint localisation of the affected
region permits genotype-phenotype correlation by com-
bining fine mapping data and clinical features [12]. The
results of the present study illustrate the flexibility and fea-
sibility of the qPCR-approach in the genetic evaluation of
MR.
The recently released high resolution array comparative
genomic hybridisation (CGH) technique [32] offers a
whole genome approach to copy number aberrations.
This technique has an enormous diagnostic capability. It
is obvious that high resolution arrays covering the whole
genome would have significant advantages over subtelo-
meric testing. At that time, array technology requires high
priced complex facilities, which are not accessible for all
diagnostic centres. In a large clinical study including 1500
mentally retarded children Shaffer et al. [32] confirmed
via whole genome array CGH technique that genomic
imbalances are frequent (5.6%) in MR. Interestingly, they
found that half of the relevant genomic imbalances
involved the subtelomeric regions. In principle, those
aberrations are detectable by subtelomeric screening as
well. As long as genome wide array CGH is significantly
more expensive, subtelomeric screening offers a reasona-
bly priced option in the diagnostic work-up of MR. At
present, costs for a medium density oligonucleotide array
are approximately 300 US$ (Agilent Human Genome
CGH 105A array, Agilent Technologies, Inc, Santa Clara,
USA), with additional expenses for further reagents, in
comparison to approximately 20 US$ reagent costs per
qPCR test for all subtelomeric regions.
The effort to clarify initially abnormal results and to dis-
tinguish between clinically insignificant CNVs and causa-
tive mutations applies to both subtelomeric screening and
whole genome array technology in the same extend. CNVs
are known to be dispersed over the genome [16]. Some of
the polymorphisms are frequent and their detection can
be avoided by appropriate assay design. Others are rare in
the population and their clinical relevance is unclear, even
if they are inherited from a normal parent. Therefore, cau-
tion is necessary in the interpretation of the significance ofMolecular Cytogenetics 2009, 2:10 http://www.molecularcytogenetics.org/content/2/1/10
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subtelomeric aberrations, especially if parental samples
are not available. The present study confirms the diagnos-
tic utility of subtelomeric qPCR with SYBR detection in
MR and the versatility of the method in determining the
extension of the detected aberrations.
Conclusion
In conclusion, this is the first report on the clinical appli-
cation of subtelomeric qPCR with SYBR green detection in
patients with idiopathic MR. The results of this study illus-
trate that this assay represents a rapid and versatile
method for the detection of subtelomeric imbalances
which implicates the option to map the breakpoint. The
qPCR method is also feasible to characterize the precise
size of imbalances. Thus, this technique is highly suitable
for genotype/phenotype studies in this patient group.
Considering the capabilities of whole genome array tech-
nologies, the application of the qPCR system is reasonable
until microarray analysis is validated and less cost inten-
sive. With a detection rate of up to 3.7% for subtelomeric
aberrations in our cohort we could confirm the results of
other large studies concerning subtelomeric aberrations in
mentally retarded patients [3].
Subjects and methods
Patients
In the present study 296 consecutive unrelated patients
were included from 2003 until 2007. Patients were col-
lected on the basis of a diagnosis of unspecific MR and/or
DD and congenital defects in newborns. Only index cases
were included in the database and patients with clinically
recognizable syndromes were excluded. The karyotypes of
all patients were normal at a 500–550 bands level. At the
time of investigation, the patients were 10 days to 49 years
of age (median 5.5 years). 4 newborns were included, of
which one (patient 3) showed an aberration. 173 patients
were male, 123 were female (ratio male/female 1.41).
Accessory clinical findings included pre- and postnatal
growth abnormalities, facial dysmorphism, non-facial
dysmorphism and structural anomalies. Those features
and family history were monitored and classified accord-
ing to the checklist developed by de Vries et al. [9] in order
to calculate an individual clinical score for each patient.
DNA was extracted from peripheral blood using standard
procedures. The study was approved by the ethics board of
the University Hospital of Göttingen, Germany.
Fluorescent Genotyping by Quantitative Real-Time PCR
QPCR with SYBR Green I was established for the detection
of subtelomeric imbalances as described [8]. We designed
two primer pairs (amplicons) for each subtelomeric
region: the first amplicon was constructed inside the
genomic sequences from the human FISH-mapped tel-
omere clone set [33] (set A), whereas the other amplicon
was mapped relatively to the subtelomeric STS-markers
inside the most telomeric clone of the human contig map
from the NCBI human databases (set B). Furthermore, we
included one amplicon for each q-arm of the acrocentric
chromosomes 13, 14, 15, 21, and 22 by selecting a
genomic sequence on the q-arm as close to the centromere
as possible.
We applied the primer set A to all patients. The second
primer set (set B) was used if an aberration was detected
with the first primer set. Some of the original amplicons
published previously [8] were replaced (see Additional
file 1 for further information). Additional primer pairs
were designed to address the size of the detected aberra-
tions in patients 1–6. All primers are listed in Additional
file 2. For primer design, qPCR conditions and analysis of
the obtained data we followed the protocol described by
Boehm et al. [8]. All primers were ordered from Operon
Biotechnologies GmbH, Cologne, Germany.
The copy number was quantified by the ABI Prism 7900
Sequence Detection System (PE Applied Biosystems, Fos-
ter City, CA, USA). Each assay was performed in duplicate
and data were analyzed using the Sequence Detection Sys-
tem software (SDS version 2.0, PE Applied Biosystems).
Reaction mixtures contained 0.25 mM of each primer and
5 ml QuantiTectt SYBR Green PCR Master Mix (Qiagen
Inc., Hilden, Germany). A melting curve analysis of PCR
products was performed routinely after finishing amplifi-
cation.
A standard curve was constructed for each amplicon with
serial dilutions of human genomic DNA of an unaffected
male individual. Absolute quantification of the amount of
the target amplicon was accomplished by measuring its
fractional cycle number value and by using the corre-
sponding logarithmic standard curve plot for linear inter-
polation. Quantitative data were normalized by
calculating the Multiple of the Median (MoM) for each
amplicon. A MoM value of 1.0 (0.8–1.2) indicated a nor-
mal diploid karyotype, and MoM values of 0.5 or 1.5 indi-
cated a monosomy or trisomy of part of the chromosome,
respectively. If results were ambiguous, e.g. a MoM value
of 1.3, the test was repeated for the specific amplicon.
Whenever possible, aberrations detected by qPCR were
confirmed by FISH using subtelomeric probes (Abbott, Des
Plaines, IL, USA; Kreatech, Amsterdam, Netherlands) and/
or via MLPA using the kits SALSA P036 and P070 human
telomere (MRC Holland, Amsterdam, Netherlands) as
described elsewhere [34]. If available, parents of probands
with subtelomeric imbalances were studied by FISH.
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